[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635639":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":22,"locations":28,"responsibleParty":45,"collaborators":10,"id":49,"slug":10,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":10,"overallStatus":64,"whyStopped":10,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Waid City Hospital, Zurich","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Patients with IgA Nephropathie and a therapy with Sparsentan",null,[12],"Drug: sparsentan",[14,19],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","sparsentan","Follow up observation of patients with IgA Nephropathy on sparsentan regarding Albuminuria and GFR",[9],{"type":15,"name":16,"description":20,"armGroupLabels":21,"otherNames":10},"follow up observation of Albuminuria and GFR in IgA patients in therapy with sparsentan",[9],[23],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Andi Schleich","CONTACT","+41 44 416 21 55","Andreas.schleich@stadtspital.ch",[29],{"facility":30,"status":10,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Stadtspital Zurich","Zurich","Canton of Zurich","8000","Switzerland","CH",{"type":37,"coordinates":38},"Point",[39,40],8.55,47.36667,{"lat":40,"lon":39},[43],{"name":24,"role":25,"phone":44,"phoneExt":10,"email":27},"+41 44 417 21 55",{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Schleich Andreas","MD","100635639",false,"NCT07555301","Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy","SWIAN","Inclusion Criteria:\n\n* IgA Nephropathy, Use of Sparsentan\n\nExclusion Criteria:\n\n* age \\\u003C 18y","ALL","18 Years",{"count":58,"type":59},50,"ESTIMATED","OBSERVATIONAL","An observational study tracking the clinical course of patients with IgA nephropathy.",[63],"IgA Nephropathy (IgAN)","NOT_YET_RECRUITING","2026-04-21",{"date":67,"type":68},"2026-04-29","ACTUAL",{"date":70,"type":59},"2026-06-01",{"date":72,"type":59},"2029-12-31",{"name":5,"class":6},1]